ArticleMarine biotechnology (New York, N.Y.)2026
Development of a Marine Algae-based Facial Cream Enriched With Phycoerythrin: Physicochemical Properties and Biological Activities.
Article in Marine biotechnology (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phycoerythrin (PE), a marine phycobiliprotein derived from Hypnea valentiae, was extracted, characterized, and evaluated for its potential application in a topical cosmeceutical formulation. The extraction yielded 6.35 mg/g (wet biomass), and spectral analysis confirmed pigment integrity. PE exhibited strong antioxidant activity, with DPPH radical scavenging increasing from 32.4% to 78.6% (20-100 µg/mL) and an IC₅₀ of 46.8 µg/mL, while the ABTS assay showed an IC₅₀ of 41.3 µg/mL. Anti-inflammatory activity revealed IC₅₀ values of 52.1 µg/mL (PE extract) and 60.5 µg/mL (PE cream), compared to 46.6 µg/mL for diclofenac sodium. Antimicrobial analysis demonstrated concentration-dependent activity. HV-PE showed moderate inhibition, whereas the PE-infused cream exhibited enhanced efficacy, with zones of inhibition up to 1.77 cm (Staphylococcus aureus), 1.81 cm (Bacillus subtilis), 1.96 cm (Escherichia coli), and 2.11 cm (Staphylococcus epidermidis) at 1000 µg/mL. MIC/MBC values further confirmed improved antibacterial performance of the cream (e.g., S. aureus: 52.34/46.21 µg/mL) compared to HV-PE. The formulated cream showed suitable physicochemical properties, with pH 7.12 (control: 7.48) and improved spreadability (80.71 g·cm/s vs. 74.79 g·cm/s). The SPF increased from 12.08 (control) to 24.04 (PE cream). Zebrafish toxicity studies indicated no observable adverse effects, confirming biocompatibility. Overall, PE demonstrates significant antioxidant, anti-inflammatory, antimicrobial, and photoprotective properties, supporting its application as a multifunctional cosmeceutical ingredient.
Indexed as
Identifiers
42635640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.